Selective COX-2 inhibitors reduce postoperative pain interference and may cut chronic pain

Design

Systematic review and meta-analysis of randomised controlled trials

Population

5,424 adults in 38 trials of perioperative COX-2 inhibitors

Primary outcome

Pain interference with daily function within 1 month

Effect

BPI interference −1.1 (−1.4 to −0.8); chronic pain OR 0.44 (0.21 to 0.93)

This meta-analysis, published in Anesthesiology, pooled 38 randomised trials (5,424 adults) comparing systemic perioperative selective COX-2 inhibitors with placebo, opioids or usual care. The primary outcome was pain interference with daily life on multidimensional tools such as the Brief Pain Inventory within a month of surgery.

COX-2 inhibitors reduced pain interference (mean difference −1.1 on a 0 to 10 scale, 95% CI −1.4 to −0.8; moderate certainty), meeting the minimal clinically important difference of 1.0. They were associated with fewer patients developing chronic pain (OR 0.44, 0.21 to 0.93; low certainty) and better quality of recovery (QoR-9 +0.84). Blood loss was slightly lower. No differences were seen in acute renal failure, GI bleeding, impaired bone healing, myocardial infarction, stroke or death.

This supports routine inclusion of a COX-2 inhibitor in multimodal analgesia for suitable patients, measured by what patients care about — function — rather than pain scores alone. Celecoxib and etoricoxib are widely available and inexpensive in India. The safety data come from trial populations, which typically under-represent higher-risk patients, so renal and cardiovascular contraindications still apply.

• Include a selective COX-2 inhibitor such as celecoxib in multimodal analgesia for suitable surgical patients.
• Screen for renal impairment, active cardiovascular disease and hypovolaemia before prescribing.
• Pair it with regular paracetamol and regional techniques where appropriate, keeping opioids for rescue.
• Measure pain interference with function, not just pain scores, when auditing analgesia.

Why it matters

It shows a benefit patients notice — less pain getting in the way of daily life — not just lower pain scores.

Don't overread it

The chronic pain result is low certainty from five trials, and trial populations typically under-represent high-risk patients.

The statistics, in plain English

A mean difference of −1.1 on a 0 to 10 scale just crosses the 1-point threshold patients perceive as meaningful. The chronic pain odds ratio of 0.44 has a wide interval (0.21 to 0.93), so the true benefit could be large or small.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.